Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Reports Strong Q4 2025 Financial Results and Highlights Pipeline Progress
Summary
Alnylam Pharmaceuticals, Inc. reported strong financial results for Q4 2025, with global net product revenues of $995 million, representing a 121% increase year-over-year. The company achieved profitability for the full year 2025, with GAAP net income of $314 million. Alnylam launched its 'Alnylam 2030' strategy, focusing on scaling through durable ATTR leadership, long-term sustainable innovation, and exceptional financial results. The company also announced 2026 pipeline goals, including 4 clinical readouts and 3 ongoing pivotal studies. Net product revenues for the full year 2025 were $2.99 billion, with $2.31 billion from TTR franchise and $500 million from Rare franchise. The company reiterated net product sales guidance for 2026, expecting growth of 64% to 77% at constant exchange rates.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement